Treatment of Herpes zoster (shingles) with a lotion containing propolis extract

Lotion containing propolis special extract GH 2002 0,5% vs. placebo in the treatment of Herpes zoster

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN17781274

Enrollment

Registered

2016-03-17

Start date

2012-02-24

Completion date

Unknown

Last updated

2016-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Herpes zoster Infections and Infestations Herpes zoster

Interventions

Participants are allocated to one of two groups using sequential allocation. Group 1: Participants are treated with acyclovir at a dose of 200 or 400 mg/day for four weeks. The participants in this g

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Aged 18 to 70 years 2. Diagnosis of Herpes zoster 3. Eligible for oral treatment with acyclovir 4. No known allergy against propolis or aciclovir

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
Pain is measured using a Visual Analogue Scale (VAS) at baseline, 3-4, 7, 14 and 28 days.	—

Secondary

Measure	Time frame
Development of Herpes zoster lesions is measured using physical assessments by the treating physician at baseline, 3-4, 7, 14 and 28 days.	—

Countries

Czech Republic

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026